Trans-sialidase overcome many antigens to be used as a vaccine candidate against Trypanosoma cruzi

BOMTEMPI I; FREITAS P; POATO A; VICCO M; RODELES L; PROCHETTO E; CABRERA G; BELUZZO B; ARIAS D; RACCA AL; GUERRERO S; MARCIPAR I

IMMUNOTHERAPY

FUTURE MEDICINE LTD

Lugar: Londres; Año: 2017

1750-743X

The development of vaccines against Trypanosoma cruzi remains in an exploratory stage. Despite several antigen candidates have been evaluated, a comparison among the performance of the immunogens cannot be carried out because the available reports differ in formulations and infection model. In this work, we compared the protective capacity of seven T. cruzi antigens in the same model of five new antigens and two well established candidates. We evaluated proteins highly immunogenic that contain tandem repeats (FRA,Tc3, Tc6); enzymes involved in metabolic pathways critical for parasite survival (cytosolic tryparedoxin peroxidase (CPX) and Tryparedoxin peroxidase (TXN); and enzymes involved in parasite invasion (Trans-sialidase (TS) and Cruzipain (CZ)). All these antigens were formulated with Freund adjuvant and protection against the parasite infection was assessed in BALB/c mice. Tc3, CPX, CZ and TS showed the best outcome after infection in survival level and parasitemia. According to this data, these groups were also assessed using the ISCOMATRIXTM 24 adjuvant whose is being used in clinical trials. Taken together, our results showed that the TS overcome the performance of other antigens when the same model is employed, confirming that TS is a promising antigen that could be used as a vaccine against T. cruzi.